Building scalable radiotheranostics with HetSiFA® chemistry
Next-generation SiFA chemistry for matched PET and radioligand therapy
Radiopharmaceuticals for matched oncology care
We are developing scalable theranostic programs built around matched imaging and therapy.
Fuzionaire Theranostics was founded to translate breakthrough silicon chemistry from Nobel laureate Robert Grubbs’ lab at Caltech into radiopharmaceutical development.
Originally developed to enable fluorine-18 PET radiopharmaceuticals, our HetSiFA® platform now supports matched diagnostic and therapeutic companions designed from common molecular architectures.
Our matched radiotheranostics connect fluorine-18 PET imaging with radioligand therapy to inform patient selection, biodistribution assessment, and prospective dosimetry.
Our programs are built for scalable imaging, therapeutic-radiometal flexibility, and oncology development paths that support strategic collaboration.
Our HetSiFA® platform
Our platform is designed to create chemically matched diagnostic and therapeutic companions from diseasetargeting peptides and other ligands, supporting rational patient selection, biodistribution assessment, and dose planning.
HetSiFAs enable PET diagnostics using either fluorine-18 or gallium-68, offering flexibility in clinical settings. Fluorine-18 is central to our scalability vision, facilitating centralized manufacturing, regional distribution, and standardized quantitative imaging across broader care networks.
In radiotheranostics, fluorine-18 functions as a scalability strategy that can broaden patient-selection capacity, reduce access barriers, and help connect more eligible patients to the right therapy.
HetSiFA-based therapeutics are developed for lutetium-177 radioligand therapy, with selective evaluation of terbium-161 and lead-212 where target biology support them.
We are also exploring endocyclic SiFA architectures as part of a broader effort to expand the design space for fluorine-18-enabled radiotheranostics.
Our focused pipeline of oncology radiotheranostics
Our lead development program, FTX-426, targets GRPR-expressing solid tumors, including prostate and breast cancer. FTX-426 is designed as a chemically matched fluorine-18/lutetium-177 theranostic pair. The modularity of our HetSiFA® platform enables focused expansion into undisclosed oncology programs and selective evaluation of therapeutic radionuclides such as terbium-161 and lead-212.
Learn MoreOur origins
We apply Fuzionaire’s silicon chemistry to develop HetSiFA® and other novel SiFA radiopharmaceutical platforms.
Read MoreOur collaborators
We work with academic, clinical, and industrial collaborators across radiochemistry, nuclear medicine, oncology, and translational development to advance HetSiFA®-based radiopharmaceutical candidates.
Get in touch
If you are interested in our HetSiFA® platform, pipeline, or strategic collaboration opportunities, we want to hear from you.
Contact